Abstract
Aim
To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men.
Methods
We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5-glycerol, gas chromatography–mass spectrometry and compartmental modelling.
Results
Compared with the placebo, ATV significantly decreased VLDL-TG concentration (−40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (−46%, p < 0.001) or ATV monotherapy (−13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (−32%, p = 0.008) or ATV (−20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo.
Conclusion
In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.
| Original language | English |
|---|---|
| Pages (from-to) | 519-526 |
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2014 |